Application No.: 10/053,753 Docket No.: 05031.0003.CNUS02

AMENDMENTS TO THE CLAIMS

1-64 (Previously cancelled)

- 65. (Previously presented) An antibody that specifically binds to a polypeptide comprising a sequence set forth in SEQ ID NO:4.
- 66. (Currently amended) An antibody that specifically binds to a polypeptide selected from the group consisting of a fragment, variant, analog, **homolog** and derivative of the sequence set forth in SEQ ID NO:4.
- 67. (Currently amended) An antibody that specifically binds to a polypeptide comprising a fusion protein, said fusion protein comprising a sequence set forth in SEQ ID NO:4, wherein said antibody specifically binds to a portion of the sequence set forth in SEQ ID NO:4.
- 68. (Previously presented) The antibody according to claim 65, wherein said antibody further comprises a label.
- 69. (Previously presented) The antibody according to claim 68, wherein said label is selected from the group consisting of an enzyme, protein, peptide, antigen, antibody, lectin, carbohydrate, biotin, avidin, radioisotope, toxin and heavy metal.
- 70. (Previously presented) The antibody according to any one of claims 65-69, wherein said antibody is a humanized antibody.
- 71. (Previously presented) The antibody according to any one of claims 65-69, wherein said antibody is a CDR-grafted antibody.
- 72. (Previously presented) The antibody according to any one of claims 65-69, wherein said antibody is a chimeric antibody.
- 73. (Previously presented) The antibody according to any one of claims 65-69, wherein said antibody is an antibody fragment.
- 74. (Previously presented) The antibody according to any one of claims 65-69, wherein said antibody is a monoclonal antibody.
- 75. (Previously presented) The antibody according to any one of claims 65-69, wherein said antibody is a polyclonal antibody.

Application No.: 10/053,753 Docket No.: 05031.0003.CNUS02

76. (Previously presented) A pharmaceutical composition comprising the antibody according to any one of claims 65-69, and a pharmaceutically acceptable adjuvant, diluent, or a carrier.

- 77. (Previously presented) A kit comprising the antibody according to any one of claims 65-69.
- 78. (New) A method of detecting altered expression of human Cyr61 in a sample comprising:
 - (a) contacting a sample with an antibody according to any one of claims 65;
 - (b) measuring binding of said antibody to said sample; and
 - (c) comparing binding of step (b) to a control, whereby altered expression of human Cyr61 is identified by a difference in binding at step (b) compared to a control.
- 79. (New) A method according to claim 78 wherein the sample is obtained from a patient in need of examining Cyr61 expression.
- 80. (New) A method of treating an angiogenic disorder, comprising administering to a subject in need thereof the composition of claim 76.
- 81. (New) A method of inhibiting cancer in a subject, comprising administering to a subject in need thereof the composition of claim 76.